KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Non Operating Income (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Other Non Operating Income for 8 consecutive years, with $6.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non Operating Income rose 18164.86% year-over-year to $6.8 million, compared with a TTM value of -$152000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of -$152000.0, changed N/A over the prior year.
  • Other Non Operating Income was $6.8 million for Q4 2025 at Biocryst Pharmaceuticals, up from -$2.7 million in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $6.8 million in Q4 2025 and bottomed at -$29.9 million in Q4 2023.
  • Average Other Non Operating Income over 3 years is -$3.3 million, with a median of -$51000.0 recorded in 2024.
  • Peak annual rise in Other Non Operating Income hit 18164.86% in 2025, while the deepest fall reached 4865.48% in 2025.
  • Year by year, Other Non Operating Income stood at -$29.9 million in 2023, then surged by 100.12% to $37000.0 in 2024, then surged by 18164.86% to $6.8 million in 2025.
  • Business Quant data shows Other Non Operating Income for BCRX at $6.8 million in Q4 2025, -$2.7 million in Q3 2025, and -$4.2 million in Q2 2025.